References

Revisiting resistant hypertension: a comprehensive review

10.1111/imj.16189 · 2023 · External reference

Evaluation and management of resistant hypertension: core curriculum 2024

10.1053/j.ajkd.2024.04.009 · 2024 · External reference

Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association

10.1161/hyp.0000000000000084 · 2018 · External reference

First-in-human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor

10.1111/cts.70000 · 2024 · External reference

Preclinical and early clinical profile of a highly selective and potent oral inhibitor of aldosterone synthase (CYP11B2)

10.1161/hypertensionaha.116.07716 · 2017 · External reference

Lorundrostat efficacy and safety in patients with uncontrolled hypertension

10.1056/nejmoa2501440 · 2025 · External reference

Emerging therapies for treatment-resistant hypertension: a review of lorundrostat and related selective aldosterone synthase inhibitors

10.1097/crd.0000000000000665 · 2026 · External reference

Efficacy and safety of aldosterone synthase inhibitors in hypertension: a systematic review and meta-analysis

10.1002/edm2.70094 · 2025 · External reference

Efficacy and safety of lorundrostat in patients with uncontrolled and treatment-resistant hypertension: a systematic review and meta-analysis

2025 · External reference

Efficacy and safety of lorundrostat in uncontrolled hypertension: a systematic review and meta-analysis

10.1111/jch.70155 · 2025 · External reference

Efficacy and safety of selective aldosterone synthase inhibitors in uncontrolled hypertension: a systematic review and meta-analysis of randomized controlled trials

10.5646/ch.2025.31.e41 · 2025 · External reference

10.1097/fjc.0000000000001850 · 2026 · Admitted local publication